非诺贝特微球对高血脂模型大鼠降脂作用研究  

Study on Lipid-lowering Effect of Fenofibrate Microspheres on Hyperlipidemia Model of Rats

作　　者：付琳 苏瑾[1] 杨春荣[1] 孙维彤[1] 张向宇[1] 孟祥祎 张杰[1] FU Lin;SU Jin;YANG Chun-rong;SUN Wei-tong;ZHANG Xiang-yu;MENG Xiang-yi;ZHANG Jie(College of Pharmacy of Jiamusi University,Heilongjiang Jiamusi 154007,China)

机构地区：[1]佳木斯大学药学院,黑龙江佳木斯154007

出　　处：《广州化工》2020年第15期91-94,共4页GuangZhou Chemical Industry

基　　金：黑龙江省属本科高校基本科研业务费科研项目(2018-KYYWF-0949)。

摘　　要：研究非诺贝特对高血脂症模型大鼠降脂作用。高效液相色谱法检测非诺贝特缓释微球载药量,进行体外释放及动物体内药效学研究等,经验证在体内具有缓释降脂作用。制备所得非诺贝特微球粒径大小均一。药物的体外释放和稳定性均符合要求,对高血脂症具有显著降脂疗效,体内高血脂动物模型的降脂试验得到良好的预期效果,为非诺贝特新剂型开发提供了良好的理论依据。The fenofibrate-loaded polymeric microspheres were prepared to study the lipid-lowering effect of hyperlipidemia model rats.The content of fenofibrate sustained-release microspheres,in vitro release and pharmacodynamics in vivo was detected by HPLC.The results showed that drug loaded microspheres were proved to have sustained-release and lipid-lowering effect.The size of fenofibrate microspheres was uniform.The release and stability of the drug in vitro met the requirements,and it had significant lipid-lowering effect on hyperlipidemia.The lipid-lowering experiment of the animal model of hyperlipidemia in vivo has achieved good expected effect,which provides a good theoretical basis for the development of new formulations of fenofibrate.

关 键 词：PLGA 非诺贝特 微球 药效学 

分 类 号：R943[医药卫生—药剂学]